ACADEMICI

ISSN: 2249-7137 Vol. 11, Issue 3, March 2021 Impact Factor: SJIF 2021 = 7.492

ACADEMICIA
An International Multidisciplinary Research Journal
(Double Blind Refereed & Peer Reviewed Journal)

DOI: 10.5958/2249-7137.2021.00605.4

POLYMORPHISM OF GENES IS FACTOR EFFICIENCY ANTI ULCER PHARMACOTHERAPY

Klichova F.K*

*Department of Pharmacology and Clinical Pharmacology,
Bukhara State Medical Institute,
UZBEKISTAN

ABSTRACT

Peptic ulcer disease is one of the variants of the typological response of the body when exogenous factors of the internal environment interact (type of the nervous system, endocrine system, psycho emotional characteristics, metabolism, biochemical reactions, and cytokine profile) with external exogenous factors. This pathology is one of the most common diseases of internal organs, and among the adult population it occurs in 7-12% of cases [1; 2; 3]. Type II stomach ulcers (Johnson H. D., 1965) or combined stomach and duodenal ulcers account for about 25% of the structure of gastric ulcers [7] According to modern research data, up to 10% of residents of Europe, the USA and Russia suffer from this disease (Ivashkin V.T., Minushkin O.N., 2015). In Uzbekistan, about 14% of people develop stomach ulcers; this disease is most common in men. (Https. // nuz.uz Jun 5, 2018) This review article also contains information on the significant effects of gene polymorphisms encoding biotransformation enzymes of drugs on the efficacy and safety of antiulcer pharmacotherapy. Determination of the polymorphism of the CYP3A5 gene makes it possible to initially determine the tactics of treatment with proton pump inhibitors in patients with peptic ulcer disease.

KEYWORDS: *Peptic ulcer disease, the prevalence of Helicobacter pylori disease, Gene polymorphisms pharmacogenetics, Pharmacotherapy.*

BIBLIOGRAPHY

1. Dalimova D.A., Abdurakhimov A.A., TurdikulovaSh.I. Distribution of Helicobacter pylori genotypes in two areas of Uzbekistan with different gastric cancer risk // European science review. – Vienna, Austria. – 2019. – V.2. - № 1-2. P.3-6. GIF 1, 36.

2. Kim K.A., Park P.W., Park J.Y. Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects//Br. J. Clin.Pharmacol. 2007, Jan. Vol.63, №1. P. 53–58.

3. Kim R. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab. Rev., 2012, 34, 47-54.

4. Kuzuya T., Kobayashi T., Moriyama N.,Nagasaka T., Yokoyama I., Uchida K., Nakao A., Nabeshima T. Amlodipine, but not MDR1polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients//Transplantation. 2003. Vol.76, №5.P. 865–868.

5. A.K. Zastrozhina, I.N. Zakharova, D.A. Sychev, E.A. Grishina, K.A. RyzhiovaAssociation of CYP3A5 (6986A>G) gene polymorphism with the effectiveness of antiinflammatory therapy in children with bro nchial asthma //Rossiyskiy vestnik perinatologii i pediatrii. – 2019. – 64 (3). – C. 73-77

6. E.E. Stupko, V.A. Shenin, L.I.Kolesnikova, A.V. Labygina, L.V. Suturina//The role of polymorphisms genes of detoxification of xenobiotics in the development of endometriosis and hysteromyoma in women // Siberian Medical Journal, 2011, № 5 c 5-8

7. M.Martinez-Matillaa, A.Blanco-Vereaa, M.Santorib, J.Ansede-Bermejob, E.Ramos-Luisa, R.Gila, AM.Bermejod, F.Lotufo-Netoe, MH.Hirataf, F.Brisighellih, M.Paramoi, A.Carracedob, M.Briona // Genetics usceptibility in pharmacodynamic and pharmacokinetic pathways underlyingdrug-induced arrhythmia and suddenun explained deaths //| Forensic Science International: Genetics 42 (2019) P. 203-212

8. Miguel A. López-García, Iris A. Feria-Romero, Héctor Serrano, Darío Rayo-Mares, Pietro Fagiolino, Marta Vázquez, Consuelo Escamilla-Núñez, Israel Grijalva, David Escalante-Santiago, Sandra Orozco-Suarez, Influence of genetic variants of CYP2D6, CYP2C9, CYP2C19 and CYP3A4 on antiepileptic drug metabolism in pediatric patients with refractory epilepsy, Pharmacological Reports, Volume 69, Issue 3, 2017, P. 504-511

9. Beridze R. M., Gritsuk A. I., Koval A. N. Targeted therapy of urinary bladder cancer by inhibiting FGFR3 signaling // Pharmacogenetics and Pharmacogenomics. - 2018. - No. 2. - P. 39-40. DOI: 10.24411 / 2588-0527-2018-10019

10. Bakieva A.R., Bogdanova T.M. The problem of peptic ulcer disease in modern society: statistical data on the Saratov region International student scientific bulletin. - 2018. - No. 5

11. Volevach L.V., Nafikova A.Sh., Khismatullina G.Ya. And other Indicators of the quality of life in persons with gastric ulcer and duodenal ulcer // Medical Bulletin of Bashkortostan. - 2016. - No. 6. - S.11-15.

12. Volevach L.V., Gabbasova L.V., Kuramshina O.A. et al. Characteristics of hereditary predisposition in duodenal ulcer // Modern problems of science and education - 2017. - No. 5. - P.

13. Gabbasova L.V., Kryukova A.Ya., Kuramshina O.A. and other Psychological components, their relationship in a patient with peptic ulcer // Psychosomatic medicine. Proceedings of the XI Intern. Congress 2016 S. 11-14.

14. Gabbasova L.V., Kryukova A.Ya. The role of social factors in the development of YABDPK // Act. Issues of human ecology. Sat mat. All-Russian scientific-practical. Conferences with international. Participation. Ufa. 2015. - Vol. 3. - S.51-56.

15. Ivashkin V.T., Lapina T.L. Gastroenterology. National leadership. GEOTAR-Media. - 2015 .- - P. 46

16. Ivashkin V.T., Sheptulin A.A., Maev I.V. and other Clinical guidelines of the Russian Gastroenterological Association for the diagnosis and treatment of peptic ulcer disease // RZhGGK. - 2016. - No. 26 (6). - S.40-54.

17. Kukes V.G., Grachev S.V., Sychev D.A., Ramenskaya G.V. Drug metabolism: scientific foundations of personalized medicine. M. - GEOTAR-Media, 2008.304 p..

18. Klichova F.K., Ochilova G.S. Significance of the MDR-1 gene in pharmacotherapy. Collection of abstracts of the II All-Russian scientific and practical conference with international participation. Pharmacotherapy safety: NOLINOCERE! Kazan, May 16, 2019 S.

19. Maev I.V., Samsonov A.A., Andreev D.N. Diseases of the stomach), Moscow: GEOTAR-Media, 2015, 1016 p.

20. Makushina A.A.1, Denisenko N.P.2, Sychev D.A.2, Ryzhikova K.A.2, Sozaeva Zh.A.2, Grishina E.A.2 CYP3A5 * 3 polymorphism and metabolic features proton pump inhibitors in patients with peptic ulcer // Pharmacogenetics and Pharmacogenomics No. 2, 2017 p. 17-22

21. Musaeva D.M., Ochilova G.S. “Significance of the MDR-1 gene in pharmacotherapy for chronic gastritis” Problems of Biology and Medicine, 2019, No. 4 (113). FROM.

22. Musaeva DM, Ochilova GS “Surunkaligastritinidavolashda MDR-1 allelvariantlariningakhamiyati” Materials of the international scientific and practical online conference “Actual issues of medical science in the XXI century” Tashkent, 25.04.2019.

23. Musaeva D.M., Ochilova G.S., Ochilov A.K., Sadullaeva G.U., Babanazarov U.T. Pharmacogenetics of chronic gastritis therapy // New day in medicine. 2020. No. 3 (31). S. 394-397.

24. Musaeva DM, Ochilova GS Importance of MDR-1 gene in pharmacotherapy of chronic gastritis // Problems of Biology and Medicine. - 2019. - №4 (113). - Б. 233-234

25. Musaeva D.M., Ochilova G.S. Influence of MDR-1 gene polymorphism on the effectiveness of treatment of chronic gastritis // Tibbiyotda yangi kun. - 2020. - No. 1 (29). - B. 309-312

26. Musaeva D.M., Ochilov A.K. Features of the CYP2C19 gene for individualization of pharmacotherapy // Tibbiyotda yangi kun. - 2020. - No. 1 (29). - B. 65-68

27. Musaeva D.M., Ochilova G.S. Significance of the MDR-1 gene in pharmacotherapy for chronic gastritis // Problems of Biology and Medicine. - 2019. - No. 4 (113). - B.

28. Ochilov A.K., G.S. Ochilova. Significance of the CYP2C19 gene in pharmacotherapy for chronic gastritis // Problems of Biology and Medicine. - 2019.- No. 4 (113). - FROM.

29. Ochilov A.K., Musaeva D.M. Treatment of chronic gastritis depending on allelic variants of the CYP2C19 gene // Mater. Scientific and practical. conf. Topical issues of medical science in the XXI century. Tashkent. - 2019. - S.

30. Ochilov A. K., Ochilova G. S. Clinical significance of CYP2C19 gene polymorphisms // University science: a look into the future. Collection of scientific. labor. by mater. International scientific. Conf. dedicated To the 85th anniversary of KSMU. - 2020. - T.I. - S. 376-379.

31. Ochilov A.K. The importance of cytochromes P450 for gastroenterology // New Day in Medicine. 2020. No. 2 (30/2). S. 57-59.

32. Ochilova G.S. Characterization of glycoprotein-P as a transporter protein of medicinal substances // New Day in Medicine. 2020. No. 2 (30/2). S. 60-63

33. Salieva M.Kh., Azizov Yu.D., Dadakhonova R.A., Musaeva D.M .. On improving health care // Achievements of science and education. 2018. No. 12 (34). S. 61-64

34. Sychev D.A., Ramenskaya G.V., Ignatiev I.V., Kukes V.G. Clinical pharmacogenetics. / Edited by Kukes V.G., Bochkova N.P. M.: Geotar-Media, 2007.248 s.

35. Sychev D.A. Recommendations for the use of pharmacogenetic testing in clinical practice. Good clinical practice. 2011; (1): 3-10.

36. Styazhkina S.N., Bekmacheva E.S., Gruzda A.M. The structure of the incidence of gastric ulcer and duodenal ulcer // International student bulletin. - 2015. - No. 2. - S.

37. Chubarova S. V., Kraposhina A.Yu., Sobko E. A., Demko I. V., Salmina A. B. Physiological and clinical aspects of P-glycoprotein // Bulletin. Issue 45. - 2012 91-97 s.